Lin Yan, Lv Yufeng, Liang Rong, Yuan Chunling, Zhang Jinyan, He Dan, Zheng Xiaowen, Zhang Jianfeng
Department of Medical Oncology, Affiliated Tumor Hospital of Guangxi Medical University.
Department of Emergency, The Second Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China.
Onco Targets Ther. 2017 Dec 21;11:29-36. doi: 10.2147/OTT.S155016. eCollection 2018.
The aim of this study was to generate a novel miRNA expression signature to accurately predict prognosis for patients with lung adenocarcinoma (LUAD).
Using expression profiles downloaded from The Cancer Genome Atlas database, we identified multiple miRNAs with differential expression between LUAD and paired healthy tissues. We then evaluated the prognostic values of the differentially expressed miRNAs using univariate/multivariate Cox regression analysis. This analysis was ultimately used to construct a four-miRNA signature that effectively predicted patient survival. Finally, we analyzed potential functional roles of the target genes for these four miRNAs using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses.
Based on our cutoff criteria (<0.05 and |log2FC| >1.0), we identified a total of 187 differentially expressed miRNAs, including 148 that were upregulated in LUAD tissues and 39 that were downregulated. Four miRNAs (miR-148a-5p, miR-31-5p, miR-548v, and miR-550a-5p) were independently associated with survival based on Kaplan-Meier analysis. We generated a signature index based on the expression of these four miRNAs and stratified patients into low- and high-risk groups. Patients in the high-risk group had significantly shorter survival times than those in the low-risk group (=0.002). A functional enrichment analysis suggested that the target genes of these four miRNAs were involved in protein phosphorylation and the Hippo and sphingolipid signaling pathways.
Taken together, our results suggest that our four-miRNA signature can be used as a prognostic tool for patients with LUAD.
本研究旨在生成一种新的微小RNA(miRNA)表达特征,以准确预测肺腺癌(LUAD)患者的预后。
利用从癌症基因组图谱数据库下载的表达谱,我们鉴定出LUAD组织与配对的健康组织之间差异表达的多个miRNA。然后,我们使用单变量/多变量Cox回归分析评估差异表达miRNA的预后价值。该分析最终用于构建一个能有效预测患者生存情况的四miRNA特征。最后,我们使用基因本体论和京都基因与基因组百科全书通路富集分析,分析这四个miRNA靶基因的潜在功能作用。
基于我们的截断标准(<0.05且|log2倍变化|>1.0),我们共鉴定出187个差异表达的miRNA,其中148个在LUAD组织中上调,39个下调。基于Kaplan-Meier分析,四个miRNA(miR-148a-5p、miR-31-5p、miR-548v和miR-550a-5p)与生存独立相关。我们基于这四个miRNA的表达生成了一个特征指数,并将患者分为低风险组和高风险组。高风险组患者的生存时间明显短于低风险组患者(=0.002)。功能富集分析表明,这四个miRNA的靶基因参与蛋白质磷酸化以及Hippo和鞘脂信号通路。
综上所述,我们的结果表明,我们的四miRNA特征可作为LUAD患者的一种预后工具。